Afuresertib(GSK2110183)|Novel Akt inhibitor|DC Chemicals

Afuresertib(GSK2110183)|Novel Akt inhibitor|DC Chemicals
Afuresertib is novel AKT inhibitor which shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma.

Catlog: DC8090| Product name: Afuresertib(GSK2110183)| Cas: 1047644-62-1| Other names: Afuresertib, GSK-2110183,GSK 2110183| Molecule Formula: C18H17Cl2FN4OS| MW: 427.32. Purity: >98%

Price: 100mg: 650 USD; 250mg: 1000 USD; 1000mg: 1900 USD

Afuresertib is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Afuresertib binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.

For research and scientific purpose only, not for human use.